

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE AUG 0 7 2003 : Symmetric Mojdeh Bahar

re Patent Application of: Harry R. Davis et al.

Serial No.: 10/057.629

Filed: January 25, 2002

For:

Use of Substituted Azetidinone

Compounds for the Treatment

Of Sitosterolemia

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Group Art Unit: 1617

Atty. Docket No.: CV01382K

## RESPONSE TO RESTRICTION REQUIREMENT AND ELECTION OF SPECIES

This is in response to the Office Action mailed on July 2, 2003, in the aboveidentified patent application.

Claims 1-58 are pending in the application. A two-way restriction requirement was set forth at page 2 of the Office Action and an election of species requirement was set forth at pages 2-3 of the Office Action. For brevity, these rejections are not repeated herein but reference is made to the Office Action. Applicants respectfully traverse and request reconsideration and withdrawal of the restriction and election of species requirements.

Applicants believe that when there is a linking claim encompassing the scope of pharmaceutical compositions comprising compounds and methods of treatment using the compositions, it is inappropriate to restrict the invention. Applicants believe that due to such commonality a complete examination of claims 1-58 would not cause undue burden. Therefore, reconsideration and withdrawal of the restriction requirement is respectfully requested.

> I hereby certify that this correspondence is being deposited with the U.S. Postal Service First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 1, 2003.

Ann Cannoni

Registration No. 35,972



## PROVISIONAL RESPONSE TO RESTRICTION REQUIREMENT AND ELECTION OF SPECIES

To facilitate prosecution of the application and in order to comply with the Examiner's requirements, Applicants hereby provisionally elect with traverse the claims of Group 1 (claims 1-24, 32-45 and 48-56) for initial examination in this application.

Applicants provisionally elect with traverse cholestyramine as the lipid-lowering agent for initial examination. Cholestyramine is a bile acid sequestrant and is disclosed at page 41, line 22 and elsewhere throughout the application. The claims readable thereon include claims 15 and 19-21, 28, 32, 43-47, and 57-58.

Applicants provisionally elect with traverse the compound of Formula (VIII) (ezetimibe) (shown at page 32 of the specification) for initial examination in this application. The claims readable thereon include claims 1, 8-9, and 13-58.

Applicants provisionally elect with traverse simvastatin as the third therapeutic agent for initial examination in this application. Simvastatin is disclosed at page 42, line 17 and elsewhere throughout the application. The claims readable thereon are claims 15-24, 28-31, 33, 41, 42 and 57.

Examination on the merits for claims 1-58 is respectfully requested.

Respectfully submitted,

ANN MARIE CANNONI Registration No. 35,972 Attorney for Applicant

Date: August 1, 2003

SCHERING CORPORATION

Patent Department, K-6-1-1990

2000 Galloping Hill Rd.

Kenilworth, NJ 07033-0530

Telephone: (908) 298-5024 Facsimile No.: (908) 298-5388 Attorney Docket No.: CV

Application No.: 10/057,629

Filing Date: 01/25/2002

Inventor: Harry R. Davis et al.

Under the Paperwork Reduction Act of 1999

AUG 0 4 2003

5

RECEIVED

AUG 0 7 2003

IECH CENTEPTO/SB92 (08-00)
Approved for use through 10/31/2002 CMB/0531003

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE required to respond to a collection of information unless it contains a valid OMB control number

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

### **Commissioner for Patents**

P.O. Box 1450

Alexandria, VA 22313-1450

on\_\_\_08/01/2003\_\_\_\_\_\_\_ Date

Signature

Ann Marie Cannoni, Reg. No. 35,972

Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents submitted:

Response to Restriction Requirement and Election Species - 2 Pages

Response Transmittal Form PTO/SB/21 - 1 Page

Certificate of Mailing - 1 Page

Post Card

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TRA	NSMITTAL FORM orrespondence after initial filing)	Fill Fir Art	U.S. Paten required to respond to a collectic plication Number ing Date st Named Inventor t Unit aminer Name	nt and Tra on of infor 10/057 01/25/ Harry 1617 Mojde	R. Davis, et al.  AHA  CENTER  THE CHOCKNERS  THE C
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request			ing(s) sing-related Papers on on to Convert to a sisional Application or of Attorney, Revocation ge of Correspondence Addre inal Disclaimer est for Refund Number of CD(s)	After Allowance Communication to Group  Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information	
Signature  Date Au  Thereby certify that this of	ngust 1, 2003	No. 35,97	E OF TRANSMISSION	N/MAIL	_ING nited States Postal Service with sufficient postage as

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.